Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499952 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
A Phase 2 study, sponsored by Nasser Hanna, M.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02499952: Clinical Trial Phase 2 study, sponsored by Nasser Hanna, M.D..
NCT02499952 is a Phase 2 study that was terminated before completion, run by Nasser Hanna, M.D.. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02499952, a Phase 2 study, was terminated before completion, sponsored by Nasser Hanna, M.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an open label, multi-institutional, single arm phase II trial of pembrolizumab in patients with incurable platinum refractory germ cell tumors. No randomization or blinding is involved.
Primary Outcome
CBR of single agent pembrolizumab in subjects with refractory germ cell tumors (GCTs), determined by sum of complete responses, partial responses, and stable disease for at least 3 months using Immune Related Response Criteria (irRC). Complete Response(irPR): Disappearance of all lesions in two consecutive observations not less than 4 wk apart. Partial Response (irPR): decrease in tumor burden ≥50 %relative to baseline confirmed by a consecutive assessment at least 4 wk after first documentati
Interventions
- DRUG Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-01-13 |
| Phase | Phase 2 |
Why NCT02499952 stopped before completion
NCT02499952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02499952 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02499952 about?
NCT02499952 is a clinical study titled "Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors". This is an open label, multi-institutional, single arm phase II trial of pembrolizumab in patients with incurable platinum refractory germ cell tumors. No randomization or blinding is involved.
What is the current status of trial NCT02499952?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-01. Estimated completion is 2017-01-13.
What interventions are being tested in trial NCT02499952?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02499952?
This trial is sponsored by Nasser Hanna, M.D., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02499952's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia